Drug-resistant Tuberculosis Treatment Market Size

Request Free Sample Copy

Report ID: 6169
Published Date: Sep 17, 2025
Report Format: PDF, PPT

Buy Now

Drug-resistant Tuberculosis Treatment Market Outlook:

Drug-resistant Tuberculosis Treatment Market size was over USD 1.68 billion in 2025 and is anticipated to cross USD 3.04 billion by 2035, witnessing more than 6.1% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of drug-resistant tuberculosis treatment is assessed at USD 1.77 billion.

The growing frequency of tuberculosis cases is driving up the drug-resistant tuberculosis market since it is the deadliest disease among all the other chronic diseases. According to WHO, 10 million people suffer from tuberculosis (TB) disease annually. This disease is preventable and curable but around 1.5 million people die every year from TB. The increasing pressure of tuberculosis in the population raises the requirement for precise diagnostic tests and treatment, which in turn is anticipated to propel the market growth.

Browse key industry insights with market data tables & charts from the report:

Drug-Resistant Tuberculosis Treatment Market Size, Trends & Forecast 2035

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of drug-resistant tuberculosis treatment is assessed at USD 1.77 billion.

The global drug-resistant tuberculosis treatment market size surpassed USD 1.68 billion in 2025 and is projected to witness a CAGR of more than 6.1%, crossing USD 3.04 billion revenue by 2035.

North America drug-resistant tuberculosis treatment market is anticipated to capture 35% share by 2035, driven by dominance of respiratory infections and large presence of key players in TB treatment.

Key players in the market include Johnson & Johnson, Novartis AG, Sanofi SA, Endo International Plc, Lupin, Hikma Pharmaceuticals, Pfizer Inc., STI Pharma LLC, Ani Pharmaceuticals, Thermo Fisher Scientific Inc..